Alere shares up as it strikes Triage deal with FDA
This article was originally published in Clinica
Executive Summary
Alere has made further progress in addressing the US FDA's concerns about its Triage tests, after agreeing new product specifications with the agency. The firm's share price surged 9% on the news, closing at $21.15 on 3 October.